German biotechnology firm MorphoSys has completed the safety run-in phase of its Phase II L-MIND trial of MOR208 combined with lenalidomide, to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL).

MOR208 is an immunotherapeutic Fc-enhanced antibody that targets CD19, which is largely expressed in different B-cell malignancies such as DLBCL and chronic lymphocytic leukemia (CLL).

The Fc-enhancement of MOR208 triggers antibody-dependent, cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

The MOR208 fuses with CD19, thereby inducing a direct apoptosis.

"We continue to investigate MOR208 in combination with lenalidomide as a potential treatment for patients with DLBCL."

The Phase II L-MIND trial is a single-arm, open-label, multicentre study of MOR208, involving about 80 patients with relapsed or refractory DLBCL who have two prior treatment histories, including an anti-CD20 targeting therapy (rituximab).

Patients applicable to high-dose chemotherapy and autologous stem cell transplantation are qualified for the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is primarily focused to determine the overall response rate (ORR).

The secondary endpoints of the trial are to determine duration of response (DoR), progression-free survival (PFS) and overall survival (OS), as well as testing the drug combination's safety and pharmacokinetic profile of MOR208.

Six patients who had been administered with MOR208 in combination with lenalidomide have displayed no negative safety signals.

MorphoSys chief development officer Dr Arndt Schottelius said: "We continue to investigate MOR208 in combination with lenalidomide as a potential treatment for patients with DLBCL.

“This is part of our broader initiative to develop MOR208 as an antibody backbone for a variety of combination partners.

“We are pleased with the initial safety run-in results from the L-MIND trial, which showed no unexpected safety signals."

The company is planning to continue with the study.